390 related articles for article (PubMed ID: 33983973)
21. Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation.
Wang SX; Ho EL; Grill M; Lee E; Peterson J; Robertson K; Fuchs D; Sinclair E; Price RW; Spudich S
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):303-10. PubMed ID: 24732871
[TBL] [Abstract][Full Text] [Related]
22. Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation.
Cheng D; Luo Z; Fu X; Stephenson S; Di Germanio C; Norris PJ; Fuchs D; Ndhlovu LC; Li QZ; Zetterberg H; Gisslen M; Price RW; Peng S; Jiang W
Microbiol Spectr; 2022 Feb; 10(1):e0197521. PubMed ID: 34985329
[TBL] [Abstract][Full Text] [Related]
23. CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection.
Gisslén M; Heslegrave A; Veleva E; Yilmaz A; Andersson LM; Hagberg L; Spudich S; Fuchs D; Price RW; Zetterberg H
Neurol Neuroimmunol Neuroinflamm; 2019 Jan; 6(1):e512. PubMed ID: 30568991
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection.
Hermansson L; Yilmaz A; Axelsson M; Blennow K; Fuchs D; Hagberg L; Lycke J; Zetterberg H; Gisslén M
J Neuroinflammation; 2019 Jan; 16(1):16. PubMed ID: 30678707
[TBL] [Abstract][Full Text] [Related]
25. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection.
Mellgren A; Price RW; Hagberg L; Rosengren L; Brew BJ; Gisslén M
Neurology; 2007 Oct; 69(15):1536-41. PubMed ID: 17923616
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study.
Ulfhammer G; Edén A; Antinori A; Brew BJ; Calcagno A; Cinque P; De Zan V; Hagberg L; Lin A; Nilsson S; Oprea C; Pinnetti C; Spudich S; Trunfio M; Winston A; Price RW; Gisslén M
Clin Infect Dis; 2022 Aug; 75(3):493-502. PubMed ID: 34747481
[TBL] [Abstract][Full Text] [Related]
27. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
[TBL] [Abstract][Full Text] [Related]
28. Increased CD38 expression on T lymphocytes as a marker of HIV dissemination into the central nervous system.
Dentone C; Fenoglio D; Schenone E; Cenderello G; Prinapori R; Signori A; Parodi A; Kalli F; Battaglia F; Feasi M; Bruzzone B; Viscoli C; Filaci G; Di Biagio A
HIV Clin Trials; 2015 Oct; 16(5):190-6. PubMed ID: 26365593
[TBL] [Abstract][Full Text] [Related]
29. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment.
Ulfhammer G; Edén A; Mellgren Å; Fuchs D; Zetterberg H; Hagberg L; Nilsson S; Yilmaz A; Gisslén M
AIDS; 2018 Sep; 32(15):2171-2178. PubMed ID: 30005007
[TBL] [Abstract][Full Text] [Related]
30. Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma.
Hellmuth J; Slike BM; Sacdalan C; Best J; Kroon E; Phanuphak N; Fletcher JLK; Prueksakaew P; Jagodzinski LL; Valcour V; Robb M; Ananworanich J; Allen IE; Krebs SJ; Spudich S
J Infect Dis; 2019 Nov; 220(12):1885-1891. PubMed ID: 30668739
[TBL] [Abstract][Full Text] [Related]
31. Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.
Joseph SB; Kincer LP; Bowman NM; Evans C; Vinikoor MJ; Lippincott CK; Gisslén M; Spudich S; Menezes P; Robertson K; Archin N; Kashuba A; Eron JJ; Price RW; Swanstrom R
Clin Infect Dis; 2019 Sep; 69(8):1345-1352. PubMed ID: 30561541
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid CD4+ T cell infection in humans and macaques during acute HIV-1 and SHIV infection.
Sharma V; Creegan M; Tokarev A; Hsu D; Slike BM; Sacdalan C; Chan P; Spudich S; Ananworanich J; Eller MA; Krebs SJ; Vasan S; Bolton DL;
PLoS Pathog; 2021 Dec; 17(12):e1010105. PubMed ID: 34874976
[TBL] [Abstract][Full Text] [Related]
33. The independent effect of drug resistance on T cell activation in HIV infection.
Hunt PW; Deeks SG; Bangsberg DR; Moss A; Sinclair E; Liegler T; Bates M; Tsao G; Lampiris H; Hoh R; Martin JN
AIDS; 2006 Mar; 20(5):691-9. PubMed ID: 16514299
[TBL] [Abstract][Full Text] [Related]
34. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia.
Schnell G; Spudich S; Harrington P; Price RW; Swanstrom R
PLoS Pathog; 2009 Apr; 5(4):e1000395. PubMed ID: 19390619
[TBL] [Abstract][Full Text] [Related]
35. Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis.
Calcagno A; Romito A; Atzori C; Ghisetti V; Cardellino C; Audagnotto S; Scarvaglieri E; Lipani F; Imperiale D; Di Perri G; Bonora S
J Neuroimmune Pharmacol; 2017 Mar; 12(1):187-193. PubMed ID: 27826896
[TBL] [Abstract][Full Text] [Related]
36. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
[TBL] [Abstract][Full Text] [Related]
37. Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection.
Sturdevant CB; Joseph SB; Schnell G; Price RW; Swanstrom R; Spudich S
PLoS Pathog; 2015 Mar; 11(3):e1004720. PubMed ID: 25811757
[TBL] [Abstract][Full Text] [Related]
38. CSF Inflammation Markers Associated with Asymptomatic Viral Escape in Cerebrospinal Fluid of HIV-Positive Individuals on Antiretroviral Therapy.
Guha D; Misra V; Yin J; Gabuzda D
Viruses; 2023 Aug; 15(9):. PubMed ID: 37766236
[TBL] [Abstract][Full Text] [Related]
39. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years.
Arnó A; Ruiz L; Juan M; Zayat MK; Puig T; Balagué M; Romeu J; Pujol R; O'Brien WA; Clotet B
AIDS; 1998 May; 12(7):697-704. PubMed ID: 9619800
[TBL] [Abstract][Full Text] [Related]
40. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
